An Unusual Presentation of Influenza-Induced Myositis

Abstract

Post-influenza myositis is considered a distinct clinical entity and is associated with muscle pain and elevated muscle enzymes during convalescence. Although the exact mechanism of muscle injury in acute viral myositis is unknown, there are possible mechanisms proposed in the literature. The progression of viral myositis to rhabdomyolysis, although uncommon, can be life-threatening and has been reported with many viruses, most commonly influenza. At our institution, a case of severe influenza-induced myositis prompted us to conduct a literature search focusing on the incidence, pathophysiology, typical presentation, and proper diagnosis of this rare condition.

Severity of Hospitalizations From SARS-CoV-2 vs Influenza and Respiratory Syncytial Virus Infection in Children Aged 5 to 11 Years in 11 US States

“…Children with RSV had the highest rate of respiratory complications (75.8%; 95% CI, 71.6%-79.9%; P = .001), whereas children with COVID-19 (without MIS-C) had the highest rate of neurologic complications (9.6%; 95% CI, 6.5%-12.8%; P = .03). Children with influenza had the highest rate of musculoskeletal complications (9.5%; 95% CI, 7.8%-11.2%; P = .001) . Children with MIS-C had the longest median (IQR) length of stay (5 [3-7] days), at a median (IQR) cost of $23 585 ($15 040-$39 122) per stay, compared with children with a diagnosis of influenza (median [IQR]: length of stay, 2 [1-4] days; cost, $5200 [$2959-$9449]).…”